Benzodiazepines are highly beneficial for managing anxiety and agitation in psychiatric inpatient settings, but we must be cautious about prescribing them to patients with substance use disorders (SUDs). Here we review strategies to reduce the risk of benzodiazepine misuse and discuss alternative medication options, including second-generation antipsychotics, antidepressants, gabapentin, and pregabalin.

A large analysis raises questions about antidepressant efficacy in certain age groups, and also finds a sweet spot.

New research calls to question the common practice of antidepressant combinations. Dr. Posternak makes sense of it.

A meta-analysis of this FDA-cleared supplement.

A meta-analysis finds little benefit, but it may depend on the type of bipolar.

Four scenarios where a time-limited approach to medication is ideal.

Placebo response rates in antidepressant trials tend to run high, making it difficult to know whether an active medication has truly beneficial effect. This research update unpacks possible reasons for this phenomenon that give you insight into how to treat your patients using a rational multimodal approach.